October 21, 2016
Merck’s Keytruda shows success in key bladder cancer trial
Merck announced that the phase 3 keynote-045 trial investigating the use of Keytruda (pembrolizumab), the company’s anti-PD-1 therapy, in patients with previously treated advanced urothelial cancer, met the primary endpoint of overall survival (OS).